Compare Novartis AG (NVS) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Qurate Retail Inc Series A — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Qurate Retail Inc Series A trades at $0.05 (market cap $698.27K). The key difference: Novartis AG is far larger — about 415670.2× Qurate Retail Inc Series A's market cap, and Novartis AG pays a 3.17% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| NVS | QVCAQ | |
|---|---|---|
Market Cap | $290.25B | $698.27K |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $15.03 |
52-Week Low | $113.50 | $0.05 |
Enterprise Value | $330.27B | $4.73B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
QVCAQ trades at $0.0515, down 12.12% in the past 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of $2.44 billion in 2025 on revenue of $9.23 billion, with negative profit margins and declining revenue trends. Cash flow improved due to financing activities, but negative equity and high debt-to-asset ratios of 77.57% highlight financial stress. Recent news includes QVC celebrating 40 years of live shopping innovation with a TikTok Shop Super Brand Day (PRNewsWire, May 28, 2026).
The outlook remains challenging due to persistent losses, high leverage, and revenue declines. Investment opportunities are limited given weak fundamentals, though low P/E and P/B ratios may attract value hunters. Key risks include bankruptcy concerns from negative equity, competitive pressures in retail, and inability to achieve profitability. Analyst sentiment is cautious, with no bullish indicators supporting near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
